08045804946
Send Inquiry
CIZUMAB 100MG INJ
2850.0 INR/Vial
Product Details:
- Pacakaging (Quantity Per Box) 1 vial per box
- Life Span 24 months from manufacturing date
- Origin of Medicine India
- Indication Metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic renal cell carcinoma, certain types of ovarian and cervical cancer
- Salt Composition Bevacizumab 100mg
- Brand Name CIZUMAB 100MG INJ
- Dosage Form Injection
- Click to View more
X
CIZUMAB 100MG INJ Price And Quantity
- 1 Number
- 2850.0 INR/Vial
- Hypersensitivity to bevacizumab or to any excipient
- C6638H10160N1720O2108S44
- Hypertension, proteinuria, bleeding, thromboembolism, gastrointestinal perforations
- Intravenous (IV) infusion only
- Hetero Healthcare Limited
- Yes
- Use immediately after opening or as directed by product insert
- Monoclonal antibody
- Not required; ready to use
- Clear to slightly opalescent solution
- L01XC07
CIZUMAB 100MG INJ Product Specifications
- Administer as intravenous infusion under medical supervision
- Bevacizumab 100mg
- Metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic renal cell carcinoma, certain types of ovarian and cervical cancer
- 1 vial
- Store in a refrigerator (2C to 8C). Do not freeze.
- Liquid
- Adults
- 24 months from manufacturing date
- 1 vial per box
- Biological/biologic drug
- India
- Anti-cancer (antineoplastic/antitumor)
- CIZUMAB 100MG INJ
- Vial
- Injection
- Cancer patients, specifically those with colorectal, lung, kidney, and certain other cancers
- 100 mg per vial; dosage as per physicians prescription
- Bevacizumab
- Hypersensitivity to bevacizumab or to any excipient
- C6638H10160N1720O2108S44
- Hypertension, proteinuria, bleeding, thromboembolism, gastrointestinal perforations
- Intravenous (IV) infusion only
- Hetero Healthcare Limited
- Yes
- Use immediately after opening or as directed by product insert
- Monoclonal antibody
- Not required; ready to use
- Clear to slightly opalescent solution
- L01XC07
CIZUMAB 100MG INJ Trade Information
- 1000 Number Per Week
- 2 Days
- No
- Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa
- All India
Product Description
- Active Ingredient: Bevacizumab (100mg per 4ml vial).
- Mechanism of Action: It is a recombinant humanized monoclonal antibody (a type of targeted therapy) that works as an anti-angiogenic agent. It selectively binds to a protein called vascular endothelial growth factor A (VEGF-A), which plays a key role in the formation of new blood vessels that supply oxygen and nutrients to tumors. By blocking VEGF-A, Cizumab effectively cuts off the tumor's blood supply, which slows down the cancer's growth and spread (metastasis).
- Administration: It is administered by a doctor or nurse as an intravenous (IV) infusion in a clinical setting. It should not be self-administered. The initial infusion typically lasts for 90 minutes and may be reduced to 30 minutes in subsequent sessions if well-tolerated.
- Storage: The medication is a solution for infusion and must be stored in a refrigerator between 2C to 8C. It should not be frozen or shaken.
Therapeutic Uses
Cizumab 100 mg is approved for the treatment of various cancers, typically when the disease is advanced or has spread (metastatic). These include:
- Metastatic colorectal cancer
- Non-small cell lung cancer (non-squamous)
- Advanced kidney cancer (renal cell carcinoma)
- Brain tumor (glioblastoma multiforme)
- Ovarian, fallopian tube, or primary peritoneal cancer
- Metastatic cervical cancer
- Hepatocellular carcinoma (liver cancer) in some cases
Targeted Cancer Treatment
CIZUMAB 100MG INJ offers an advanced, targeted approach to cancer therapy using bevacizumab, a monoclonal antibody. This biological drug interrupts tumor growth by blocking the formation of new blood vessels, thereby limiting nutrient supply to cancer cells and restraining their proliferation. Its efficacy in various forms of cancer ensures broader therapeutic reach.
Ready-to-Use and Convenient
No reconstitution is needed with CIZUMAB 100MG INJ; it arrives as a liquid solution, enabling direct preparation and administration by healthcare professionals. This reduces potential errors during mixing and supports efficiency in clinical settings, ensuring rapid and safe delivery of care to cancer patients.
Strict Handling and Safety
CIZUMAB 100MG INJ requires refrigeration (2C to 8C) and should never be frozen. After opening, it must be used immediately unless otherwise advised by the product insert to maintain medication safety and efficacy. Proper handling according to instructions is necessary for optimal results and patient well-being.
FAQ's of CIZUMAB 100MG INJ:
Q: How should CIZUMAB 100MG INJ be administered?
A: CIZUMAB 100MG INJ is given only as an intravenous (IV) infusion under strict medical supervision. The dosage and infusion rate must be determined by a healthcare professional based on the patient's condition and type of cancer being treated.Q: What conditions is CIZUMAB 100MG INJ used to treat?
A: This medication is prescribed for adults with metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic renal cell carcinoma, and selected ovarian and cervical cancers, as determined by your physician.Q: When should this injection be used after opening the vial?
A: It is recommended to use CIZUMAB 100MG INJ immediately after opening the vial. If not, follow the exact guidelines in the product insert provided with the medication for safe use.Q: Where should CIZUMAB 100MG INJ be stored?
A: Store the vial in a refrigerator at 2C to 8C. Avoid freezing the medication, as improper storage may diminish its effectiveness.Q: What are the common side effects of CIZUMAB 100MG INJ?
A: Possible adverse effects include hypertension, proteinuria, bleeding, thromboembolic events, and, in rare instances, gastrointestinal perforations. Always report any unusual symptoms to your healthcare provider promptly.Q: Who should not use CIZUMAB 100MG INJ?
A: Individuals with known hypersensitivity to bevacizumab or any excipients in the formulation should avoid this medication. Discuss your medical history and allergies with your doctor before starting therapy.Q: What are the main benefits of using CIZUMAB 100MG INJ?
A: CIZUMAB 100MG INJ helps inhibit tumor growth through its anti-angiogenic action, potentially improving survival rates and clinical outcomes in eligible cancer patients receiving proper medical supervision.Tell us about your requirement
Price:
Quantity
Select Unit
- 50
- 100
- 200
- 250
- 500
- 1000+
Additional detail
Mobile number
Email
Other Products in 'Anti Cancer Medicines' category
Contact Us
- Office No. - 5, Ground Floor, D R Shopping Center, Dattapada Road, Near Hdfc Bank, Borivali East,Mumbai - 400066, Maharashtra, India
- Phone : 08045804946
- Mr Ranjeet Singh (CEO & Founder)
- Mobile : 08045804946
- medisus.pharma007@gmail.com
Send Inquiry
Send SMS
Call Me FreeMEDISUS PHARMA
All Rights Reserved.(Terms of Use)
Developed and Managed by Infocom Network Private Limited.
Developed and Managed by Infocom Network Private Limited.
